At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

When high levels of low-density lipoprotein cholesterol (LDL-C or bad cholesterol) are untreated for a long time, they lead to the accumulation of fatty plaques in the arteries. These plaques clog the ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

We seek to educate our people on inclusivity and provide all associates with equal opportunities to contribute to our company and advance their careers. We listen to different communities with a ...

The Drug Supply Chain Security Act (DSCSA) is federal legislation passed in 2013 that creates national requirements for tracing pharmaceutical products throughout the entire supply chain. This new ...

Thanks to our innovative medicines, Novartis is a world-renowned company. Novartis develops medicines that are protected by patents and sold only on prescription. These medications meet the high ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each ...

Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study 1 More than 80 ...